Test Details: Eighty percent of patients with gastrointestinal stromal tumor (GIST) have a C-KIT mutation in exon 9, 11, 13, or 17. c-Kit mutations are associated with shorter survival and higher relapse risk following standard therapy in AML Patients. It also confirms diagnosis of Systemic Mastocytosis where patients without the D816V pathogenic variation are sensitive to the tyrosine kinase inhibitor Imatinib mesylate (Imatinib).